Institution
Casa Sollievo della Sofferenza
Healthcare•San Giovanni Rotondo, Italy•
About: Casa Sollievo della Sofferenza is a healthcare organization based out in San Giovanni Rotondo, Italy. It is known for research contribution in the topics: Population & Cancer. The organization has 2234 authors who have published 6183 publications receiving 239811 citations. The organization is also known as: Home for Relief of the Suffering.
Topics: Population, Cancer, Gene, Diabetes mellitus, Type 2 diabetes
Papers published on a yearly basis
Papers
More filters
••
Fausto Castagnetti1, Gabriele Gugliotta1, Michele Baccarani1, Massimo Breccia2 +150 more•Institutions (25)
TL;DR: The characteristics of CML or the host response to leukemia differ with age, and the knowledge of these differences and of their causes may help to refine the treatment and to improve the outcome.
70 citations
••
University of Kiel1, University of the Basque Country2, University of Barcelona3, University of Milan4, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico5, Humanitas University6, Oslo University Hospital7, Monash University, Clayton campus8, University of Alcalá9, University of Milano-Bicocca10, Casa Sollievo della Sofferenza11, University of Turin12, Spanish National Research Council13, University of Lübeck14, Carlos III Health Institute15, University of Seville16, University of Oslo17
TL;DR: The first robust genetic susceptibility loci for the development of respiratory failure in Covid-19 are reported, and Identified variants may help guide targeted exploration of severe Covd-19 pathophysiology.
Abstract: The IKMB's core facilities received infrastructure support by the
Deutsche Forschungsgemeinschaft (DFG) Cluster of Excellence "Precision Medicine in Chronic
Inflammation" (PMI, EXC2167). The project also received support through a philanthropic
donation by Stein Erik Hagen and Canica AS. L.V. was funded by the Fondazione IRCCS Ca’
Granda «COVID-19 Biobank» research grant. This
work was also supported by the Ministero dell’Istruzione, dell’Universita e della Ricerca – MIUR
project "Dipartimenti di Eccellenza 2018 – 2022" (n° D15D18000410001) to the Department of
Medical Sciences, University of Torino. The IKMB authors
received financial support from the UKSH Foundation "Gutes Tun!" (special thanks to Alexander
Eck, Jenspeter Horst and Jens Scholz) and the German Federal Ministry of Education and Research
(BMBF; grant ID 01KI20197). HLA-Typing was performed and supported by the Stefan-MorschStiftung. M.A.H was supported by the Spanish Ministry of Science and Innovation ‘JdC fellowship
IJC2018-035131-I.
70 citations
••
TL;DR: PTC patients with positive serum Tg Ab titer during the first year after primary treatment were more likely to have persistent/recurrent disease than those who were consistently TgAb-negative, and negative titers at 1 year may be associated with more favorable outcomes.
Abstract: Objective: The association between papillary thyroid cancer (PTC) and Hashimoto's thyroiditis is widely recognized, but less is known about the possible link between circulating anti-thyroglobulin antibody (TgAb) titers and PTC aggressiveness. To shed light on this issue, we retrospectively examined a large series of PTC patients with and without positive TgAb.
Methods: Data on 220 TgAb-positive PTC patients (study cohort) were retrospectively collected in 10 hospital-based referral centers. All the patients had undergone near-total thyroidectomy with or without radioiodine remnant ablation. Tumor characteristics and long-term outcomes (follow-up range: 2.5–24.8 years) were compared with those recently reported in 1020 TgAb-negative PTC patients with similar demographic characteristics. We also assessed the impact on clinical outcome of early titer disappearance in the TgAb-positive group.
Results: At baseline, the study cohort (mean age 45.9 years, range 12.5–84.1 years; 85% female) had a significantly higher prevalence of high-risk patients (6.9% vs. 3.2%, p<0.05) and extrathyroidal tumor extension (28.2% vs. 24%; p<0.0001) than TgAb-negative controls. Study cohort patients were also more likely than controls to have persistent disease at the 1-year visit (13.6% vs. 7.0%, p=0.001) or recurrence during subsequent follow-up (5.8% vs. 1.4%, p=0.0001). At the final follow-up visit, the percentage of patients with either persistent or recurrent disease in the two cohorts was significantly different (6.4% of TgAb-positive patients vs. 1.7% in the TgAb-negative group, p<0.0001). At the 1-year visit, titer normalization was observed in 85 of the 220 TgAb-positive individuals. These patients had a significantly lower rate of persistent disease than those who were still TgAb positive (8.2% vs. 17.3%. p=0.05), and no relapses were observed among patients with no evidence of disease during subsequent follow-up.
Conclusions: PTC patients with positive serum TgAb titer during the first year after primary treatment were more likely to have persistent/recurrent disease than those who were consistently TgAb-negative. Negative titers at 1 year may be associated with more favorable outcomes.
69 citations
••
Istituto Superiore di Sanità1, Princess Margaret Cancer Centre2, Linköping University3, Boston Children's Hospital4, Casa Sollievo della Sofferenza5, Stanford University6, Lawrence Berkeley National Laboratory7, United States Department of Energy8, Otto-von-Guericke University Magdeburg9, University of Rome Tor Vergata10, Charles University in Prague11, Catholic University of the Sacred Heart12, Paris Diderot University13, Icahn School of Medicine at Mount Sinai14, New York University15
TL;DR: It is reported that missense mutations altering Son of Sevenless, Drosophila, homolog 2 (SOS2), which encodes a RAS guanine nucleotide exchange factor, occur in a small percentage of subjects with NS, and mutations were found to promote enhanced signaling from RAS to ERK.
Abstract: The RASopathies constitute a family of autosomal-dominant disorders whose major features include facial dysmorphism, cardiac defects, reduced postnatal growth, variable cognitive deficits, ectodermal and skeletal anomalies, and susceptibility to certain malignancies. Noonan syndrome (NS), the commonest RASopathy, is genetically heterogeneous and caused by functional dysregulation of signal transducers and regulatory proteins with roles in the RAS/extracellular signal-regulated kinase (ERK) signal transduction pathway. Mutations in known disease genes account for approximately 80% of affected individuals. Here, we report that missense mutations altering Son of Sevenless, Drosophila, homolog 2 (SOS2), which encodes a RAS guanine nucleotide exchange factor, occur in a small percentage of subjects with NS. Four missense mutations were identified in five unrelated sporadic cases and families transmitting NS. Disease-causing mutations affected three conserved residues located in the Dbl homology (DH) domain, of which two are directly involved in the intramolecular binding network maintaining SOS2 in its autoinhibited conformation. All mutations were found to promote enhanced signaling from RAS to ERK. Similar to NS-causing SOS1 mutations, the phenotype associated with SOS2 defects is characterized by normal development and growth, as well as marked ectodermal involvement. Unlike SOS1 mutations, however, those in SOS2 are restricted to the DH domain.
69 citations
••
Marche Polytechnic University1, University of Milan2, Università Campus Bio-Medico3, University of Brescia4, University of Verona5, University of Turin6, University of Palermo7, University of Cagliari8, University of Messina9, Casa Sollievo della Sofferenza10, University of Modena and Reggio Emilia11, European Institute of Oncology12
TL;DR: It is suggested that age, ECOG-PS, histology, MSKCC score, TTBM and the presence of concomitant metastases should be considered in order to optimize the management of RCC patients with BMs.
Abstract: Aim of this study was to investigate for the presence of existing prognostic factors in patients with bone metastases (BMs) from RCC since bone represents an unfavorable site of metastasis for renal cell carcinoma (mRCC). Data of patients with BMs from RCC were retrospectively collected. Age, sex, ECOG-Performance Status (PS), MSKCC group, tumor histology, presence of concomitant metastases to other sites, time from nephrectomy to bone metastases (TTBM, classified into three groups: 5 years) and time from BMs to skeletal-related event (SRE) were included in the Cox analysis to investigate their prognostic relevance. 470 patients were enrolled in this analysis. In 19 patients (4%),bone was the only metastatic site; 277 patients had concomitant metastases in other sites. Median time to BMs was 16 months (range 0 − 44y) with Median OS of 17 months. Number of metastatic sites (including bone, p = 0.01), concomitant metastases, high Fuhrman grade (p 5 years had longer OS (22 months) compared to patients with TTBM <1 year (13 months) or between 1 and 5 years (19 months) from nephrectomy (p < 0.001), no difference was found between these two last groups (p = 0.18). At multivariate analysis, ECOG-PS, MSKCC group and concomitant lung or lymph node metastases were independent predictors of OS in patients with BMs. Our study suggest that age, ECOG-PS, histology, MSKCC score, TTBM and the presence of concomitant metastases should be considered in order to optimize the management of RCC patients with BMs.
69 citations
Authors
Showing all 2237 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ralph B. D'Agostino | 226 | 1287 | 229636 |
Cisca Wijmenga | 136 | 668 | 86572 |
Massimo Mangino | 116 | 369 | 84902 |
Xavier Estivill | 110 | 673 | 59568 |
Andrea Natale | 106 | 945 | 52520 |
Stefano Pileri | 100 | 635 | 43369 |
Bruno Dallapiccola | 94 | 935 | 43208 |
Fortunato Ciardiello | 94 | 695 | 47352 |
F. Bianchi | 91 | 1370 | 40011 |
Paolo Gasparini | 91 | 431 | 36059 |
Joseph G. Gleeson | 86 | 307 | 23345 |
Mario Rizzetto | 79 | 470 | 33693 |
Giuseppe Leone | 74 | 654 | 21451 |
Maurizio Pompili | 74 | 783 | 20649 |
Massimo Rugge | 74 | 594 | 25624 |